Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Probiotics for Inflammatory Bowel Disease; A Deep Dive into their Impact on Disease Course and Associated Health Risks

Author(s): Wassan Nori Mohammed Hassan*, Methaq Mueen Al-kaabi, Nabeeha Najatee Akram, Mustafa Ali Kassim Kassim and Alexandru Cosmin Pantazi

Volume 31, Issue 30, 2024

Published on: 30 April, 2024

Page: [4807 - 4825] Pages: 19

DOI: 10.2174/0109298673314861240429072352

Price: $65

Abstract

To date, the underlying pathology of inflammatory bowel disease (IBD) is undetermined. Disturbance of intestinal gut microbiota was implicated in many health diseases, including IBD. Increasing evidence suggests that probiotics play a beneficial role in restoring the balance of the gut ecosystem. This review searched multiple databases for relevant works that examined probiotics' possible benefits in adults with IBD. Probiotic mode of action in ulcerative colitis patients and Crohn's disease were examined with respect to probiotic strain, their benefits, and their advantages in adult cases. Eligible studies for inclusion were assessed and analyzed. They were effective in reducing IBD disease course, inducing and maintaining remission, particularly for ulcerative colitis patients, with good efficacy and safety profile. However, the evidence for Crohn's disease was lacking. Probiotics positively affect IBD-related risks, reducing the risk of gastrointestinal malignancy and optimizing treating them. Additionally, they improved reduced fertility odds for both genders. The osteoporosis risk among IBD patients was also reduced, although the duration of use and dose were still not established. There was an encouraging role for them in reducing IBD -cardiovascular risks among cases with acute myocardial infarction and those with chronic heart failure. Finally, they had novel use in reducing IBD-related depression and improved overall mental health. In conclusion, we recommend probiotics as an adjuvant therapeutic option for IBD therapy for ulcerative colitis; however, their role in Crohn's disease needs further research.

« Previous Next »
[1]
Agrawal, M.; Allin, K.H.; Petralia, F.; Colombel, J.F.; Jess, T. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat. Rev. Gastroenterol. Hepatol., 2022, 19(6), 399-409.
[http://dx.doi.org/10.1038/s41575-022-00593-y] [PMID: 35301463]
[2]
Liu, X.Y.; Tang, H.; Zhou, Q.Y.; Zeng, Y.L.; Chen, D.; Xu, H.; Li, Y.; Tan, B.; Qian, J.M. Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology. World J. Gastroenterol., 2023, 29(2), 272-285.
[http://dx.doi.org/10.3748/wjg.v29.i2.272] [PMID: 36687128]
[3]
Stange, E.F. Current and future aspects of IBD research and treatment: The 2022 perspective. Frontline Gastroenterol., 2022, 1, 914371.
[http://dx.doi.org/10.3389/fgstr.2022.914371]
[4]
Saez, A.; Herrero-Fernandez, B.; Gomez-Bris, R.; Sánchez-Martinez, H.; Gonzalez-Granado, J.M. Pathophysiology of inflammatory bowel disease: Innate immune system. Int. J. Mol. Sci., 2023, 24(2), 1526.
[http://dx.doi.org/10.3390/ijms24021526] [PMID: 36675038]
[5]
Spiegel, B. Gravity and the gut: A hypothesis of irritable bowel syndrome. Am. J. Gastroenterol., 2022, 117(12), 1933-1947.
[http://dx.doi.org/10.14309/ajg.0000000000002066] [PMID: 36455220]
[6]
Chey, W.D.; Kurlander, J.; Eswaran, S. Irritable bowel syndrome: A clinical review. JAMA, 2015, 313(9), 949-958.
[http://dx.doi.org/10.1001/jama.2015.0954] [PMID: 25734736]
[7]
Falloon, K.A.; Fiocchi, C. Current therapy in inflammatory bowel disease: Why and how we need to change? EMJ innov., 2022, 6(1), 40-49.
[http://dx.doi.org/10.33590/emjinnov/21-00134]
[8]
Selvamani, S.; Mehta, V.; Ali El Enshasy, H.; Thevarajoo, S.; El Adawi, H.; Zeini, I.; Pham, K.; Varzakas, T.; Abomoelak, B. Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: A recent update. Saudi J. Biol. Sci., 2022, 29(5), 3546-3567.
[http://dx.doi.org/10.1016/j.sjbs.2022.02.044] [PMID: 35844369]
[9]
Mishra, J.; Stubbs, M.; Kuang, L.; Vara, N.; Kumar, P.; Kumar, N. Inflammatory bowel disease therapeutics: A focus on probiotic engineering. Mediators Inflamm., 2022, 2022, 9621668.
[http://dx.doi.org/10.1155/2022/9621668]
[10]
Marafini, I.; Monteleone, G. Precision medicine in inflammatory bowel diseases. Front. Pharmacol., 2021, 12, 653924.
[http://dx.doi.org/10.3389/fphar.2021.653924] [PMID: 33927628]
[11]
Singh, T.P.; Natraj, B.H. Next-generation probiotics: A promising approach towards designing personalized medicine. Crit. Rev. Microbiol., 2021, 47(4), 479-498.
[http://dx.doi.org/10.1080/1040841X.2021.1902940] [PMID: 33822669]
[12]
Huang, C.; Hao, W.; Wang, X.; Zhou, R.; Lin, Q. Probiotics for the treatment of ulcerative colitis: A review of experimental research from 2018 to 2022. Front. Microbiol., 2023, 14, 1211271.
[http://dx.doi.org/10.3389/fmicb.2023.1211271] [PMID: 37485519]
[13]
König, J.; Wells, J.; Cani, P.D.; García-Ródenas, C.L.; MacDonald, T.; Mercenier, A.; Whyte, J.; Troost, F.; Brummer, R.J. Human intestinal barrier function in health and disease. Clin. Transl. Gastroenterol., 2016, 7(10), e196.
[http://dx.doi.org/10.1038/ctg.2016.54] [PMID: 27763627]
[14]
Kałużna, A.; Olczyk, P.; Komosińska-Vassev, K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J. Clin. Med., 2022, 11(2), 400.
[http://dx.doi.org/10.3390/jcm11020400] [PMID: 35054093]
[15]
Loddo, I.; Romano, C. Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front. Immunol., 2015, 6, 551.
[http://dx.doi.org/10.3389/fimmu.2015.00551] [PMID: 26579126]
[16]
Magro, F.; Langner, C.; Driessen, A.; Ensari, A.; Geboes, K.; Mantzaris, G.J.; Villanacci, V.; Becheanu, G.; Nunes, P.B.; Cathomas, G.; Fries, W.; Jouret-Mourin, A.; Mescoli, C.; de Petris, G.; Rubio, C.A.; Shepherd, N.A.; Vieth, M.; Eliakim, R. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis, 2013, 7(10), 827-851.
[http://dx.doi.org/10.1016/j.crohns.2013.06.001] [PMID: 23870728]
[17]
Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[18]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 2009, 6(7), e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[19]
Fijan, S. Probiotics and their antimicrobial effect. Microorganisms, 2023, 11(2), 528.
[http://dx.doi.org/10.3390/microorganisms11020528] [PMID: 36838493]
[20]
Adak, A.; Khan, M.R. An insight into gut microbiota and its functionalities. Cell. Mol. Life Sci., 2019, 76(3), 473-493.
[http://dx.doi.org/10.1007/s00018-018-2943-4] [PMID: 30317530]
[21]
Shankar, J. Food habit associated mycobiota composition and their impact on human health. Front. Nutr., 2021, 8, 773577.
[http://dx.doi.org/10.3389/fnut.2021.773577] [PMID: 34881282]
[22]
Seibold, F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut, 2005, 54(9), 1212-1213.
[http://dx.doi.org/10.1136/gut.2005.065227] [PMID: 16099786]
[23]
Vermeire, S.; Peeters, M.; Vlietinck, R.; Joossens, S.; Hond, E.D.; Bulteel, V.; Bossuyt, X.; Geypens, B.; Rutgeerts, P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families. Inflamm. Bowel Dis., 2001, 7(1), 8-15.
[http://dx.doi.org/10.1097/00054725-200102000-00002] [PMID: 11233666]
[24]
Pantazi, A.C.; Kassim, M.A.K.; Nori, W.; Tuta, L.A.; Mihai, C.M.; Chisnoiu, T.; Balasa, A.L.; Mihai, L.; Lupu, A.; Frecus, C.E.; Lupu, V.V.; Chirila, S.I.; Badescu, A.G.; Hangan, L.T.; Cambrea, S.C. Clinical perspectives of gut microbiota in patients with chronic kidney disease and end-stage kidney disease: Where do we stand? Biomedicines, 2023, 11(9), 2480.
[http://dx.doi.org/10.3390/biomedicines11092480] [PMID: 37760920]
[25]
Ronan, V.; Yeasin, R.; Claud, E.C. Childhood development and the microbiome-the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology, 2021, 160(2), 495-506.
[http://dx.doi.org/10.1053/j.gastro.2020.08.065] [PMID: 33307032]
[26]
Ranjha, M.M.A.N.; Shafique, B.; Batool, M.; Kowalczewski, P.Ł.; Shehzad, Q.; Usman, M.; Manzoor, M.F.; Zahra, S.M.; Yaqub, S.; Aadil, R.M. Nutritional and health potential of probiotics: A review. Appl. Sci., 2021, 11(23), 11204.
[27]
Piccioni, A.; Cicchinelli, S.; Valletta, F.; De Luca, G.; Longhitano, Y.; Candelli, M.; Ojetti, V.; Sardeo, F.; Navarra, S.; Covino, M.; Franceschi, F. Gut microbiota and autoimmune diseases: A charming real world together with probiotics. Curr. Med. Chem., 2022, 29(18), 3147-3159.
[http://dx.doi.org/10.2174/0929867328666210922161913] [PMID: 34551690]
[28]
Nori, W.; Akram, N.N.; Mueen Al-kaabi, M. Probiotics in women and pediatrics health; A narrative review. AMJ, 2023, 19(1), 10-16.
[http://dx.doi.org/10.33091/amj.2023.138442.1021]
[29]
Cianci, R.; Franza, L.; Massaro, M.G.; Borriello, R.; Tota, A.; Pallozzi, M.; De Vito, F.; Gambassi, G. The crosstalk between gut microbiota, intestinal immunological niche and visceral adipose tissue as a new model for the pathogenesis of metabolic and inflammatory diseases: The paradigm of type 2 diabetes mellitus. Curr. Med. Chem., 2022, 29(18), 3189-3201.
[http://dx.doi.org/10.2174/0929867329666220105121124] [PMID: 34986766]
[30]
Palai, S.; Derecho, C.M.P.; Kesh, S.S.; Egbuna, C.; Onyeike, P.C. Pre-biotics, probiotics, synbiotics and its importance in the management of diseases. In: Functional Foods and Nutraceuticals; Springer International Publishing: Cham, 2020; pp. 173-196.
[http://dx.doi.org/10.1007/978-3-030-42319-3_10]
[31]
Khan, I.; Ullah, N.; Zha, L.; Bai, Y.; Khan, A.; Zhao, T.; Che, T.; Zhang, C. Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens, 2019, 8(3), 126.
[http://dx.doi.org/10.3390/pathogens8030126] [PMID: 31412603]
[32]
Santana, P.T.; Rosas, S.L.B.; Ribeiro, B.E.; Marinho, Y.; de Souza, H.S.P. Dysbiosis in inflammatory bowel disease: Pathogenic role and potential therapeutic targets. Int. J. Mol. Sci., 2022, 23(7), 3464.
[http://dx.doi.org/10.3390/ijms23073464] [PMID: 35408838]
[33]
DeGruttola, A.K.; Low, D.; Mizoguchi, A.; Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. Inflamm. Bowel Dis., 2016, 22(5), 1137-1150.
[http://dx.doi.org/10.1097/MIB.0000000000000750] [PMID: 27070911]
[34]
Zheng, J.; Sun, Q.; Zhang, J.; Ng, S.C. The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. United European Gastroenterol. J., 2022, 10(10), 1091-1102.
[http://dx.doi.org/10.1002/ueg2.12338] [PMID: 36461896]
[35]
Di Tommaso, N.; Gasbarrini, A.; Ponziani, F.R. Intestinal barrier in human health and disease. Int. J. Environ. Res. Public Health, 2021, 18(23), 12836.
[http://dx.doi.org/10.3390/ijerph182312836] [PMID: 34886561]
[36]
Sultan, S.; El-Mowafy, M.; Elgaml, A.; Ahmed, T.A.E.; Hassan, H.; Mottawea, W. Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease. Front. Physiol., 2021, 12, 715506.
[http://dx.doi.org/10.3389/fphys.2021.715506] [PMID: 34646151]
[37]
Florio, M.; Crudele, L.; Moschetta, A.; Gadaleta, R.M. Discovering the nutrition-microbiota interplay in inflammatory bowel disease: Are we there yet? In: Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk. Endocrinology; Springer, Cham, 2024; pp. 333-371.
[38]
Fiorindi, C.; Russo, E.; Balocchini, L.; Amedei, A.; Giudici, F. Inflammatory bowel disease and customized nutritional intervention focusing on gut microbiome balance. Nutrients, 2022, 14(19), 4117.
[http://dx.doi.org/10.3390/nu14194117] [PMID: 36235770]
[39]
Zhang, Y.; Si, X.; Yang, L.; Wang, H.; Sun, Y.; Liu, N. Association between intestinal microbiota and inflammatory bowel disease. Animal Model. Exp. Med., 2022, 5(4), 311-322.
[http://dx.doi.org/10.1002/ame2.12255] [PMID: 35808814]
[40]
Valvano, M.; Capannolo, A.; Cesaro, N.; Stefanelli, G.; Fabiani, S.; Frassino, S.; Monaco, S.; Magistroni, M.; Viscido, A.; Latella, G. Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients, 2023, 15(17), 3824.
[http://dx.doi.org/10.3390/nu15173824] [PMID: 37686856]
[41]
Gordon, H.; Burisch, J.; Ellul, P.; Karmiris, K.; Katsanos, K.; Allocca, M.; Bamias, G.; Barreiro-De Acosta, M.; Braithwaite, T.; Greuter, T. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J. Crohn’s Colitis, 2023, 18(1), 1-37.
[http://dx.doi.org/10.1093/ecco-jcc/jjac187]
[42]
Markowiak-Kopeć, P.; Śliżewska, K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients, 2020, 12(4), 1107.
[http://dx.doi.org/10.3390/nu12041107] [PMID: 32316181]
[43]
Tiwari, S.K. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front. Cell. Infect. Microbiol., 2022, 12, p. 851140.
[44]
Manoharan, D.; Natesan, S.; Billamboz, M.; Jawhara, S. Role of bacteria-derived exopolysaccharides in inflammatory bowel disease with a special focus on cyanobacterial exopolysaccharides. Appl. Microbiol., 2024, 4(1), 250-274.
[http://dx.doi.org/10.3390/applmicrobiol4010017]
[45]
Latif, A.; Shehzad, A.; Niazi, S.; Zahid, A.; Ashraf, W.; Iqbal, M.W.; Rehman, A.; Riaz, T.; Aadil, R.M.; Khan, I.M.; Özogul, F.; Rocha, J.M.; Esatbeyoglu, T.; Korma, S.A. Probiotics: mechanism of action, health benefits and their application in food industries. Front. Microbiol., 2023, 14, 1216674.
[http://dx.doi.org/10.3389/fmicb.2023.1216674] [PMID: 37664108]
[46]
Liu, Y.; Wang, J.; Wu, C. Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front. Nutr., 2022, 8, 634897.
[http://dx.doi.org/10.3389/fnut.2021.634897] [PMID: 35047537]
[47]
Cristofori, F.; Dargenio, V.N.; Dargenio, C.; Miniello, V.L.; Barone, M.; Francavilla, R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: A door to the body. Front. Immunol., 2021, 12, 578386.
[http://dx.doi.org/10.3389/fimmu.2021.578386] [PMID: 33717063]
[48]
Mascarenhas, M.T.; de Melo, S.O.; Cunha, A.C.L.A.; Ferreira, I.C. Systematic review: Does the use of probiotics generate benefits for patients treating inflammatory intestinal disease? Rev. Med., 2023, 102(3), 201379.
[http://dx.doi.org/10.11606/issn.1679-9836.v102i3e-201379]
[49]
Nakamura, Y.; Suzuki, S.; Murakami, S.; Nishimoto, Y.; Higashi, K.; Watarai, N.; Umetsu, J.; Ishii, C.; Ito, Y.; Mori, Y.; Kohno, M.; Yamada, T.; Fukuda, S. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT. Comput. Struct. Biotechnol. J., 2022, 20, 5847-5858.
[http://dx.doi.org/10.1016/j.csbj.2022.10.026] [PMID: 36382178]
[50]
Bjarnason, I.; Sission, G.; Hayee, B.H. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology, 2019, 27(3), 465-473.
[http://dx.doi.org/10.1007/s10787-019-00595-4] [PMID: 31054010]
[51]
Caviglia, G.P.; De Blasio, F.; Vernero, M.; Armandi, A.; Rosso, C.; Saracco, G.M.; Bugianesi, E.; Astegiano, M.; Ribaldone, D.G. Efficacy of a preparation based on calcium butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study. J. Clin. Med., 2021, 10(21), 4961.
[http://dx.doi.org/10.3390/jcm10214961] [PMID: 34768480]
[52]
Darb Emamie, A.; Rajabpour, M.; Ghanavati, R.; Asadolahi, P.; Farzi, S.; Sobouti, B.; Darbandi, A. The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009–2020. J. Appl. Microbiol., 2021, 130(6), 1823-1838.
[http://dx.doi.org/10.1111/jam.14907] [PMID: 33098703]
[53]
Agraib, L.M.; Yamani, M.I.; Tayyem, R.; Abu-Sneineh, A.T.; Rayyan, Y.M. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. Clin. Nutr. ESPEN, 2022, 51, 83-91.
[http://dx.doi.org/10.1016/j.clnesp.2022.08.020] [PMID: 36184252]
[54]
Kaur, L.; Gordon, M.; Baines, P.A.; Iheozor-Ejiofor, Z.; Sinopoulou, V.; Akobeng, A.K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2020, 3(3), CD005573.
[55]
Naseer, M.; Poola, S.; Ali, S.; Samiullah, S.; Tahan, V. Prebiotics and probiotics in inflammatory bowel disease: Where are we now and where are we going? Curr. Clin. Pharmacol., 2020, 15(3), 216-233.
[http://dx.doi.org/10.2174/22123938MTA1pMTY42] [PMID: 32164516]
[56]
Kamarli Altun, H.; Akal Yildiz, E.; Akin, M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turk. J. Gastroenterol., 2019, 30(4), 313-320.
[http://dx.doi.org/10.5152/tjg.2019.18356] [PMID: 30666969]
[57]
van der Waal, M.B.; Flach, J.; Browne, P.D.; Besseling-van der Vaart, I.; Claassen, E.; van de Burgwal, L.H.M. Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. PharmaNutrition, 2019, 7, 100139.
[http://dx.doi.org/10.1016/j.phanu.2018.100139]
[58]
Matsuoka, K.; Uemura, Y.; Kanai, T.; Kunisaki, R.; Suzuki, Y.; Yokoyama, K.; Yoshimura, N.; Hibi, T. Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Dig. Dis. Sci., 2018, 63(7), 1910-1919.
[http://dx.doi.org/10.1007/s10620-018-4946-2] [PMID: 29450747]
[59]
Sun, Y.Y.; Li, M.; Li, Y.Y.; Li, L.X.; Zhai, W.Z.; Wang, P.; Yang, X.X.; Gu, X.; Song, L.J.; Li, Z.; Zuo, X.L.; Li, Y.Q. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep., 2018, 8(1), 2964.
[http://dx.doi.org/10.1038/s41598-018-21241-z] [PMID: 29445178]
[60]
Palumbo, V.D.; Romeo, M.; Gammazza, A.M.; Carini, F.; Damiani, P.; Damiano, G.; Buscemi, S.; Lo Monte, A.I.; Gerges-Geagea, A.; Jurjus, A.; Tomasello, G. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomedical Papers, 2016, 160.
[http://dx.doi.org/10.5507/bp.2016.044]
[61]
Fedorak, R.N.; Feagan, B.G.; Hotte, N.; Leddin, D.; Dieleman, L.A.; Petrunia, D.M.; Enns, R.; Bitton, A.; Chiba, N.; Paré, P.; Rostom, A.; Marshall, J.; Depew, W.; Bernstein, C.N.; Panaccione, R.; Aumais, G.; Steinhart, A.H.; Cockeram, A.; Bailey, R.J.; Gionchetti, P.; Wong, C.; Madsen, K. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin. Gastroenterol. Hepatol., 2015, 13(5), 928-935.e2.
[http://dx.doi.org/10.1016/j.cgh.2014.10.031] [PMID: 25460016]
[62]
Shadnoush, M.; Hosseini, R.S.; Khalilnezhad, A.; Navai, L.; Goudarzi, H.; Vaezjalali, M. Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: A double-blind, placebo-controlled clinical trial. Korean J. Gastroenterol., 2015, 65(4), 215-221.
[http://dx.doi.org/10.4166/kjg.2015.65.4.215] [PMID: 25896155]
[63]
Petersen, A.M.; Mirsepasi, H.; Halkjær, S.I.; Mortensen, E.M.; Nordgaard-Lassen, I.; Krogfelt, K.A. Ciprofloxacin and probiotic Escherichia coli nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J. Crohns Colitis, 2014, 8
[http://dx.doi.org/10.1016/j.crohns.2014.06.001]
[64]
Yoon, J.S.; Sohn, W.; Lee, O.Y.; Lee, S.P.; Lee, K.N.; Jun, D.W.; Lee, H.L.; Yoon, B.C.; Choi, H.S.; Chung, W.S.; Seo, J.G. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol., 2014, 29(1), 52-59.
[http://dx.doi.org/10.1111/jgh.12322] [PMID: 23829297]
[65]
Sniffen, J.C.; McFarland, L.V.; Evans, C.T.; Goldstein, E.J.C. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One, 2018, 13(12), e0209205.
[http://dx.doi.org/10.1371/journal.pone.0209205] [PMID: 30586435]
[66]
Mora, D.; Filardi, R.; Arioli, S.; Boeren, S.; Aalvink, S.; de Vos, W.M. Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: The case of VSL#3. Microb. Biotechnol., 2019, 12(6), 1371-1386.
[http://dx.doi.org/10.1111/1751-7915.13476] [PMID: 31402586]
[67]
Kruis, W.; Schütz, E.; Fric, P.; Fixa, B.; Judmaier, G.; Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 1997, 11(5), 853-858.
[http://dx.doi.org/10.1046/j.1365-2036.1997.00225.x] [PMID: 9354192]
[68]
Jia, K.; Tong, X.; Wang, R.; Song, X. The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. Medicine, 2018, 97(51), e13792.
[69]
Gionchetti, P.; Rizzello, F.; Venturi, A.; Brigidi, P.; Matteuzzi, D.; Bazzocchi, G.; Poggioli, G.; Miglioli, M.; Campieri, M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology, 2000, 119(2), 305-309.
[http://dx.doi.org/10.1053/gast.2000.9370] [PMID: 10930365]
[70]
Bibiloni, R.; Fedorak, R.N.; Tannock, G.W.; Madsen, K.L.; Gionchetti, P.; Campieri, M.; De Simone, C.; Sartor, R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol., 2005, 100(7), 1539-1546.
[http://dx.doi.org/10.1111/j.1572-0241.2005.41794.x] [PMID: 15984978]
[71]
Guslandi, M.; Mezzi, G.; Sorghi, M.; Testoni, P.A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig. Dis. Sci., 2000, 45(7), 1462-1464.
[http://dx.doi.org/10.1023/A:1005588911207] [PMID: 10961730]
[72]
Limketkai, B.N.; Akobeng, A.K.; Gordon, M.; Adepoju, A.A. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2020, 7(7), CD006634.
[73]
Chua, K.J.; Ling, H.; Hwang, I.Y.; Lee, H.L.; March, J.C.; Lee, Y.S.; Chang, M.W. An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in in vitro inflammatory bowel disease models. ACS Biomater. Sci. Eng., 2023, 9(9), 5123-5135.
[http://dx.doi.org/10.1021/acsbiomaterials.2c00202] [PMID: 36399014]
[74]
Chua, K.J.; Kwok, W.C.; Aggarwal, N.; Sun, T.; Chang, M.W. Designer probiotics for the prevention and treatment of human diseases. Curr. Opin. Chem. Biol., 2017, 40, 8-16.
[http://dx.doi.org/10.1016/j.cbpa.2017.04.011] [PMID: 28478369]
[75]
Falloon, K.; Cohen, B.; Ananthakrishnan, A.N.; Barnes, E.L.; Bhattacharya, A.; Colombel, J.F.; Cross, R.K.; Driscoll, M.S.; Fernandez, A.P.; Ha, C.; Herfarth, H.; Horst, S.; Hou, J.; Husni, M.E.; Kroshinsky, D.; Kuhn, K.A.; Lowder, C.Y.; Martin, G.; Parikh, D.; Sayed, C.J.; Schocket, L.; Siaton, B.C.; Vedak, P.; Weisman, M.H.; Rieder, F. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2022, 55(9), 1179-1191.
[http://dx.doi.org/10.1111/apt.16853] [PMID: 35277863]
[76]
Wan, Q.; Zhao, R.; Xia, L.; Wu, Y.; Zhou, Y.; Wang, Y.; Cui, Y.; Shen, X.; Wu, X.T. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: A meta-analysis of 26 observational studies. J. Cancer Res. Clin. Oncol., 2021, 147(4), 1077-1087.
[http://dx.doi.org/10.1007/s00432-020-03496-0] [PMID: 33433655]
[77]
Hassan, D.S.; Hasary, H.J.; Hassan, Z.S. Role of probiotics in the prevention and treatment of GIT cancers: Updated review. AJMS, 2023, 4, 52-59.
[http://dx.doi.org/10.54133/ajms.v4i.103]
[78]
D’Amico, F.; Barone, M.; Tavella, T.; Rampelli, S.; Brigidi, P.; Turroni, S. Host microbiomes in tumor precision medicine: How far are we? Curr. Med. Chem., 2022, 29(18), 3202-3230.
[http://dx.doi.org/10.2174/0929867329666220105121754] [PMID: 34986765]
[79]
Javanmard, A.; Ashtari, S.; Sabet, B.; Davoodi, S.H.; Rostami-Nejad, M.; Esmaeil Akbari, M.; Niaz, A.; Mortazavian, A.M. Probiotics and their role in gastrointestinal cancers prevention and treatment; An overview. Gastroenterol. Hepatol. Bed Bench, 2018, 11(4), 284-295.
[PMID: 30425806]
[80]
Nori, W.; Kassim, M.A.K.; Pantazi, A.C. Probiotics role in reducing GIT cancer-related therapy side effects. In: AJMS; , 2023; 5, pp. 114-115.
[81]
Huang, V.W.; Chang, H.J.; Kroeker, K.I.; Goodman, K.J.; Hegadoren, K.M.; Dieleman, L.A.; Fedorak, R.N. Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease? Can. J. Gastroenterol. Hepatol., 2015, 29(2), 95-103.
[http://dx.doi.org/10.1155/2015/715354] [PMID: 25803020]
[82]
Nori, W.; Shallal, F.; Zghair, M.A.G. Aspirin effect on mid luteal phase doppler indices in patients with recurrent pregnancy loss. Int. J. Pharm. Res., 2020, 12(3), 2929.
[http://dx.doi.org/10.31838/ijpr/2020.12.03.413]
[83]
Tavernier, N.; Fumery, M.; Peyrin-Biroulet, L.; Colombel, J.F.; Gower-Rousseau, C. Systematic review: Fertility in non-surgically treated inflammatory bowel disease. Aliment. Pharmacol. Ther., 2013, 38(8), 847-853.
[http://dx.doi.org/10.1111/apt.12478] [PMID: 24004045]
[84]
Vincenti, A.; Loperfido, F.; De Giuseppe, R.; Manuelli, M.; Bosoni, D.; Righi, A.; Nappi, R.E.; Cena, H. Crohn’s disease and female infertility: Can nutrition play a supporting role? Nutrients, 2022, 14(12), 2423.
[http://dx.doi.org/10.3390/nu14122423] [PMID: 35745153]
[85]
Cai, H.; Cao, X.; Qin, D.; Liu, Y.; Liu, Y.; Hua, J.; Peng, S. Gut microbiota supports male reproduction via nutrition, immunity, and signaling. Front. Microbiol., 2022, 13, 977574.
[http://dx.doi.org/10.3389/fmicb.2022.977574] [PMID: 36060736]
[86]
Feng, T.; Wang, J. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: A systematic review. Gut Microbes, 2020, 12(1), 1801944.
[http://dx.doi.org/10.1080/19490976.2020.1801944] [PMID: 32795116]
[87]
Magill, R.G.; MacDonald, S.M. Male infertility and the human microbiome. Front Reprod Health., 2023, 5, 1166201.
[88]
Lewandowski, K.; Kaniewska, M.; Więcek, M.; Szwarc, P.; Panufnik, P.; Tulewicz-Marti, E.; Walicka, M.; Franek, E.; Rydzewska, G. Risk factors for osteoporosis among patients with inflammatory bowel disease—do we already know everything? Nutrients, 2023, 15(5), 1151.
[http://dx.doi.org/10.3390/nu15051151] [PMID: 36904150]
[89]
Roomi, A.B.; Nori, W.; Al-Badry, S.H. The value of serum adiponectin in osteoporotic women: Does weight have an effect? J. Obes., 2021, 2021, 1-5.
[http://dx.doi.org/10.1155/2021/5325813] [PMID: 34796028]
[90]
Seeman, E.; Martin, T.J. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat. Rev. Rheumatol., 2019, 15(4), 225-236.
[http://dx.doi.org/10.1038/s41584-019-0172-3] [PMID: 30755735]
[91]
Akram, N.N.; Jaafar, M.M.; Abdulqader, S.K.; Nori, W.; Kassim, M.A.K.; Pantazi, A.C. Clinical characteristics and therapeutic management of osteogenesis imperfecta in Iraqi children. AJMS, 2023, 5, S189-S194.
[http://dx.doi.org/10.54133/ajms.v5i1S.416]
[92]
Chen, Z.; Cai, Z.; Zhuang, P.; Li, F.; Cui, W.; Li, Z. Living probiotic biomaterials for osteoporosis therapy. Biomedical Technology, 2023, 1, 52-64.
[http://dx.doi.org/10.1016/j.bmt.2022.11.007]
[93]
Chen, Y.C.; Greenbaum, J.; Shen, H.; Deng, H.W. Association between gut microbiota and bone health: Potential mechanisms and prospective. J. Clin. Endocrinol. Metab., 2017, 102(10), 3635-3646.
[http://dx.doi.org/10.1210/jc.2017-00513] [PMID: 28973392]
[94]
Lan, H.; Liu, W.H.; Zheng, H.; Feng, H.; Zhao, W.; Hung, W.L.; Li, H. Bifidobacterium lactis BL-99 protects mice with osteoporosis caused by colitis via gut inflammation and gut microbiota regulation. Food Funct., 2022, 13(3), 1482-1494.
[http://dx.doi.org/10.1039/D1FO02218K] [PMID: 35060590]
[95]
Harahap, I.A.; Suliburska, J. Can probiotics decrease the risk of postmenopausal osteoporosis in women? PharmaNutrition, 2023, 24, 100336.
[http://dx.doi.org/10.1016/j.phanu.2023.100336]
[96]
Sleutjes, J.A.M.; van der Woude, C.J.; Verploegh, P.J.P.; Aribas, E.; Kavousi, M.; Roeters van Lennep, J.E.; de Vries, A.C. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population. Eur. J. Prev. Cardiol., 2023, 30(15), 1615-1622.
[http://dx.doi.org/10.1093/eurjpc/zwad124] [PMID: 37075221]
[97]
Bunu, D.M.; Timofte, C.E.; Ciocoiu, M.; Floria, M.; Tarniceriu, C.C.; Barboi, O.B.; Tanase, D.M. Cardiovascular manifestations of inflammatory bowel disease: Pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract., 2019, 2019, 3012509.
[98]
Dixon, A.; Robertson, K.; Yung, A.; Que, M.; Randall, H.; Wellalagodage, D.; Cox, T.; Robertson, D.; Chi, C.; Sun, J. Efficacy of probiotics in patients of cardiovascular disease risk: A systematic review and meta-analysis. Curr. Hypertens. Rep., 2020, 22(9), 74.
[http://dx.doi.org/10.1007/s11906-020-01080-y] [PMID: 32860083]
[99]
Biondi, R.B.; Salmazo, P.S.; Bazan, S.G.Z.; Hueb, J.C.; Paiva, S.A.R.; Sassaki, L.Y. Cardiovascular risk in individuals with inflammatory bowel disease. Clin. Exp. Gastroenterol., 2020, 13, 107-113.
[http://dx.doi.org/10.2147/CEG.S243478] [PMID: 32425576]
[100]
Zhai, T.; Wang, P.; Hu, X.; Zheng, L. Probiotics bring new hope for atherosclerosis prevention and treatment. Oxid. Med. Cell Longev., 2022, 2022, 3900835.
[http://dx.doi.org/10.1155/2022/3900835]
[101]
Longoria, C.R.; Guers, J.J.; Campbell, S.C. The Interplay between cardiovascular disease, exercise, and the gut microbiome. Rev. Cardiovasc. Med., 2022, 23(11), 365.
[http://dx.doi.org/10.31083/j.rcm2311365]
[102]
Kelly, T.N.; Bazzano, L.A.; Ajami, N.J.; He, H.; Zhao, J.; Petrosino, J.F.; Correa, A.; He, J. Gut microbiome associates with lifetime cardiovascular disease risk profile among bogalusa heart study participants. Circ. Res., 2016, 119(8), 956-964.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309219] [PMID: 27507222]
[103]
Han, Y.; Gong, Z.; Sun, G.; Xu, J.; Qi, C.; Sun, W.; Jiang, H.; Cao, P.; Ju, H. Dysbiosis of gut microbiota in patients with acute myocardial infarction. Front. Microbiol., 2021, 12, 680101.
[http://dx.doi.org/10.3389/fmicb.2021.680101] [PMID: 34295318]
[104]
Qian, X.; Liu, A.; Liang, C.; He, L.; Xu, Z.; Tang, S. Analysis of gut microbiota in patients with acute myocardial infarction by 16S rRNA sequencing. Ann. Transl. Med., 2022, 10(24), 1340.
[http://dx.doi.org/10.21037/atm-22-5671] [PMID: 36660636]
[105]
Zhong, X.; Zhao, Y.; Huang, L.; Liu, J.; Wang, K.; Gao, X.; Zhao, X.; Wang, X. Remodeling of the gut microbiome by Lactobacillus johnsonii alleviates the development of acute myocardial infarction. Front. Microbiol., 2023, 14, 1140498.
[http://dx.doi.org/10.3389/fmicb.2023.1140498] [PMID: 36970663]
[106]
Gomes, T.T.; Mangini, S.; Marcondes-Braga, F.G.; Avila, M.S.; Campos, I.W.; Santos, F.B.; Seguro, L.F.; Bacal, F. Influence of probiotic supplementation in inflammatory profile of patients with heart failure - study PROBHF: A clinical trial, randomized, double-blind, placebo-controlled. J. Heart Lung Transplant., 2022, 41(4), S203.
[http://dx.doi.org/10.1016/j.healun.2022.01.1645]
[107]
Moludi, J.; Saiedi, S.; Ebrahimi, B.; Alizadeh, M.; Khajebishak, Y.; Ghadimi, S.S. Probiotics supplementation on cardiac remodeling following myocardial infarction: A single-center double-blind clinical study. J. Cardiovasc. Transl. Res., 2021, 14(2), 299-307.
[http://dx.doi.org/10.1007/s12265-020-10052-1] [PMID: 32681453]
[108]
Moludi, J.; Alizadeh, M.; Mohammadzad, M.H.S.; Davari, M. The effect of probiotic supplementation on depressive symptoms and quality of life in patients after myocardial infarction: Results of a preliminary double-blind clinical trial. Psychosom. Med., 2019, 81(9), 770-777.
[http://dx.doi.org/10.1097/PSY.0000000000000749] [PMID: 31592939]
[109]
Wu, Z.X.; Li, S.F.; Chen, H.; Song, J.X.; Gao, Y.F.; Zhang, F.; Cao, C.F. The changes of gut microbiota after acute myocardial infarction in rats. PLoS One, 2017, 12(7), e0180717.
[http://dx.doi.org/10.1371/journal.pone.0180717] [PMID: 28686722]
[110]
Costanza, A.C.; Moscavitch, S.D.; Faria Neto, H.C.C.; Mesquita, E.T. Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial. Int. J. Cardiol., 2015, 179, 348-350.
[http://dx.doi.org/10.1016/j.ijcard.2014.11.034] [PMID: 25464484]
[111]
Yuan, X.; Chen, B.; Duan, Z.; Xia, Z.; Ding, Y.; Chen, T.; Liu, H.; Wang, B.; Yang, B.; Wang, X.; Liu, S.; Zhou, J.Y.; Liu, Y.; Wang, Q.; Shen, Z.; Xiao, J.; Shang, H.; Liu, W.; Shi, G.; Zhu, L.; Chen, Y. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes, 2021, 13(1), 1987779.
[http://dx.doi.org/10.1080/19490976.2021.1987779] [PMID: 34806521]
[112]
Sasso, J.M.; Ammar, R.M.; Tenchov, R.; Lemmel, S.; Kelber, O.; Grieswelle, M.; Zhou, Q.A. Gut microbiome-brain alliance: A landscape view into mental and gastrointestinal health and disorders. ACS Chem. Neurosci., 2023, 14(10), 1717-1763.
[http://dx.doi.org/10.1021/acschemneuro.3c00127] [PMID: 37156006]
[113]
Sharma, A.; Sharma, V. The gut-brain connection: A case report on depression in ulcerative colitis and novel treatment approach. Cureus, 2023, 15(11), e48462.
[http://dx.doi.org/10.7759/cureus.48462] [PMID: 38073991]
[114]
Darmadi, D.; Ariestine, D.A.; Surja, S.S. Role of probiotics in inflammatory bowel disease. Rawal Med. J., 2023, 48(2), p. 537.
[115]
Bremmer, A. The efficacy and role of probiotics for maintenance of remission in crohn’s disease: A meta-analysis and survey. Open J. Gastroenterol., 2023, 13(5), 171-198.
[http://dx.doi.org/10.4236/ojgas.2023.135018]
[116]
Vakadaris, G.; Stefanis, C.; Giorgi, E.; Brouvalis, M.; Voidarou, C.C.; Kourkoutas, Y.; Tsigalou, C.; Bezirtzoglou, E. The role of probiotics in inducing and maintaining remission in Crohn’s disease and ulcerative colitis: A systematic review of the literature. Biomedicines, 2023, 11(2), 494.
[http://dx.doi.org/10.3390/biomedicines11020494] [PMID: 36831029]
[117]
Zhang, X.F.; Guan, X.X.; Tang, Y.J.; Sun, J.F.; Wang, X.K.; Wang, W.D.; Fan, J.M. Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: A systematic review and meta-analysis. Eur. J. Nutr., 2021, 60(5), 2855-2875.
[http://dx.doi.org/10.1007/s00394-021-02503-5] [PMID: 33555375]
[118]
Pabón-Carrasco, M.; Ramirez-Baena, L.; Vilar-Palomo, S.; Castro-Méndez, A.; Martos-García, R.; Rodríguez-Gallego, I. Probiotics as a coadjuvant factor in active or quiescent inflammatory bowel disease of adults-A meta-analytical study. Nutrients, 2020, 12(9), 2628.
[http://dx.doi.org/10.3390/nu12092628] [PMID: 32872272]
[119]
Dore, M.P.; Bibbò, S.; Fresi, G.; Bassotti, G.; Pes, G.M. Side effects associated with probiotic use in adult patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. Nutrients, 2019, 11(12), 2913.
[http://dx.doi.org/10.3390/nu11122913] [PMID: 31810233]
[120]
Eindor-Abarbanel, A.; Healey, G.R.; Jacobson, K. Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood. Int. J. Mol. Sci., 2021, 22(22), 12506.
[http://dx.doi.org/10.3390/ijms222212506] [PMID: 34830388]
[121]
Lomer, M.C.E.; Wilson, B.; Wall, C.L. British dietetic association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease. J. Hum. Nutr. Diet., 2023, 36(1), 336-377.
[http://dx.doi.org/10.1111/jhn.13054] [PMID: 35735908]
[122]
Szajewska, H.; Berni Canani, R.; Domellöf, M.; Guarino, A.; Hojsak, I.; Indrio, F.; Lo Vecchio, A.; Mihatsch, W.A.; Mosca, A.; Orel, R.; Salvatore, S.; Shamir, R.; van den Akker, C.H.P.; van Goudoever, J.B.; Vandenplas, Y.; Weizman, Z. Probiotics for the management of pediatric gastrointestinal disorders: Position paper of the ESPGHAN special interest group on gut microbiota and modifications. J. Pediatr. Gastroenterol. Nutr., 2023, 76(2), 232-247.
[http://dx.doi.org/10.1097/MPG.0000000000003633] [PMID: 36219218]
[123]
Müller, L.; Lorentz, A. Probiotics in the treatment of inflammatory bowel diseases in adulthood: A systematic review. J. Gastrointestin. Liver Dis., 2022, 31(1), 74-84.
[124]
Aghamohammad, S.; Sepehr, A.; Miri, S.T.; Najafi, S.; Pourshafie, M.R.; Rohani, M. The role of combining probiotics in preventing and controlling inflammation: A focus on the anti-inflammatory and immunomodulatory effects of probiotics in an in vitro model of IBD. Can. J. Gastroenterol. Hepatol., 2022, 2022, 1-9.
[http://dx.doi.org/10.1155/2022/2045572] [PMID: 36397951]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy